2013
DOI: 10.1371/journal.pone.0083378
|View full text |Cite
|
Sign up to set email alerts
|

Activation of Phospholipase C Mimics the Phase Shifting Effects of Light on Melatonin Rhythms in Retinal Photoreceptors

Abstract: Many aspects of retinal photoreceptor function and physiology are regulated by the circadian clocks in these cells. It is well established that light is the primary stimulus that entrains these clocks; yet, the biochemical cascade(s) mediating light’s effects on these clocks remains unknown. This deficiency represents a significant gap in our fundamental understanding of photoreceptor signaling cascades and their functions. In this study, we utilized re-aggregated spheroid cultures prepared from embryonic chic… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…While we saw a tendency of decreased TRPM8 activity with the PLC activator alone ( m -3M3FBS 25 µM), we could reproduce the reduction of TRPM8 activity by oxaliplatin (oxaliplatin: p = 0.003; oxaliplatin ±10 µM PLC agonist: p < 0.0001; oxaliplatin ±25 µM PLC agonist: p < 0.0019). Additional treatment with the PLC activator ( m -3M3FBS [ 30 ], 10 µM and 25 µM for 24 h) did not cause additional reduction of TRPM8 activity, indicating that the desensitizing effect of oxaliplatin on TRPM8 activity may already be at maximum and cannot be further potentiated by additional PLC activation ( Figure 3 D,E).…”
Section: Resultsmentioning
confidence: 99%
“…While we saw a tendency of decreased TRPM8 activity with the PLC activator alone ( m -3M3FBS 25 µM), we could reproduce the reduction of TRPM8 activity by oxaliplatin (oxaliplatin: p = 0.003; oxaliplatin ±10 µM PLC agonist: p < 0.0001; oxaliplatin ±25 µM PLC agonist: p < 0.0019). Additional treatment with the PLC activator ( m -3M3FBS [ 30 ], 10 µM and 25 µM for 24 h) did not cause additional reduction of TRPM8 activity, indicating that the desensitizing effect of oxaliplatin on TRPM8 activity may already be at maximum and cannot be further potentiated by additional PLC activation ( Figure 3 D,E).…”
Section: Resultsmentioning
confidence: 99%